Epizyme Revenue 2012-2022 | EPZM
Epizyme revenue from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Epizyme Annual Revenue
(Millions of US $) |
| 2021 |
$37 |
| 2020 |
$16 |
| 2019 |
$24 |
| 2018 |
$22 |
| 2017 |
$10 |
| 2016 |
$8 |
| 2015 |
$3 |
| 2014 |
$41 |
| 2013 |
$68 |
| 2012 |
$45 |
| 2011 |
$7 |
Epizyme Quarterly Revenue
(Millions of US $) |
| 2022-03-31 |
$9 |
| 2021-12-31 |
$12 |
| 2021-09-30 |
$5 |
| 2021-06-30 |
$13 |
| 2021-03-31 |
$8 |
| 2020-12-31 |
$8 |
| 2020-09-30 |
$4 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$6 |
| 2019-06-30 |
$6 |
| 2019-03-31 |
$8 |
| 2018-12-31 |
$10 |
| 2018-09-30 |
|
| 2018-06-30 |
$12 |
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$10 |
| 2017-03-31 |
|
| 2016-12-31 |
$0 |
| 2016-09-30 |
$7 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$0 |
| 2015-06-30 |
$1 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$10 |
| 2014-09-30 |
$8 |
| 2014-06-30 |
$9 |
| 2014-03-31 |
$13 |
| 2013-12-31 |
$36 |
| 2013-09-30 |
$8 |
| 2013-06-30 |
$15 |
| 2013-03-31 |
$9 |
| 2012-12-31 |
|
| 2012-09-30 |
$15 |
| 2012-06-30 |
$15 |
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.087B |
$0.037B |
|
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
|
